ArticleMalaria journal2026
Molecular markers of antimalarial drug resistance in pfk13, pfmdr1, pfdhfr, and pfdhps genes of Plasmodium falciparum in a rural municipality in Cubal, Benguela Province, Angola (2022-2023).
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a major cause of morbidity and mortality in Angola, where Plasmodium falciparum accounts for most infections. The widespread use of artemether-lumefantrine (AL) as first-line treatment and sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) exerts selective pressure on local parasite populations. Molecular surveillance of drug resistance markers is essential to monitor susceptibility and anticipate changes that may influence treatment and prevention strategies. This study analyzed pfk13, pfmdr1, pfdhfr, and pfdhps polymorphisms in P. falciparum isolates from Cubal, Benguela province, to assess parasite genetic evolution under AL and SP pressure.
methodsA cross-sectional study was conducted between 2022 and 2023 at Hospital Nossa Senhora da Paz (Cubal). A total of 139 real-time PCR-confirmed P. falciparum infections were included. Dried blood spot samples underwent sequencing of the genes involved in resistance. Mutation and haplotype frequencies associated with antimalarial resistance were determined.
resultsAmong 120 pfk13 sequences, mutations were detected in 12 isolates (10%), including five nonsynonymous variants, but none corresponded to validated or candidate markers of artemisinin resistance. In pfmdr1 (100 sequences), Y184F was the most prevalent mutation (43%), N86Y was rare (1%), and D1246Y was not detected. Seven additional pfmdr1 variants were identified. Of the 101 isolates correctly sequenced for pfdhfr/pfdhps, 77.2% carried the triple pfdhfr N51I/C59R/S108N mutation. In pfdhps, A437G was nearly fixed (98%), K540E showed moderate prevalence (23.8%), and A581G was absent. The most common pfdhps haplotypes were ISGKAA (64.4%) and ISGEAA (22.8%). Combined pfdhfr/pfdhps profiles classified 58.4% of isolates as "partially resistant" (IRNG) and 17.8% as "fully resistant" (IRNGE), with no "super-resistant" haplotypes. Additional single mutations not associated with SP resistance were also detected.
conclusionsThis study provides an updated molecular profile of antimalarial resistance in a rural area of Angola. No validated or candidate pfk13 markers of artemisinin resistance were identified. However, the predominance of pfmdr1 haplotypes linked to reduced lumefantrine susceptibility raises concerns regarding AL efficacy. Although SP remains suitable for IPTp, the presence of the "fully resistant" haplotype (IRNGE) of pfdhfr/pfdhps highlight potential risks to long-term effectiveness. These findings reinforce the need for integrated molecular surveillance and periodic therapeutic efficacy studies to guide malaria control policies in rural Angola.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.